“ANALYTICAL METHODS FOR THE ESTIMATION OF SAFINAMIDE AND LEVODOPA: A COMPREHENSIVE REVIEW”
Main Article Content
Keywords
Parkinson's disease, Safinamide, Levodopa, Drug profile, Pharmacopeial methods, Validation
Abstract
Parkinson's disease is a chronic neurological disorder that primarily impacts movement. It occurs when specific brain cells that produce a chemical known as dopamine begin to die. This results in common symptoms such as difficulties with balance, stiff muscles, lack of movement, and shaking. Parkinson's disease patients may also experience non-motor symptoms such as anxiety or depression, issues with memory, or trouble falling asleep. While there is no cure, various treatments have been developed to help manage the symptoms of Parkinson's disease. Management of PD is a growing field and targets new treatment methods, as well as improvements to old ones. Pharmacological, surgical, and therapeutic treatments have allowed physicians to treat not only the main motor symptoms of Parkinson's disease. Medications like levodopa and safinamide are widely used to manage its symptoms. Levodopa is the most effective treatment for improving motor function, as it helps replenish dopamine levels. Safinamide is an add-on therapy used in combination with levodopa, which works by inhibiting monoamine oxidase-B (MAO-B) and modulating glutamate release. This combination helps reduce motor fluctuations and “off” periods, improving patients’ overall mobility and quality of life. Together, these treatments play a vital role in improving symptom control in individuals living with Parkinson’s disease, though ongoing research continues to seek a true cure.
KEYWORDS:
References
2. Kalia LV, Lang AE. “Parkinson’s disease.” Lancet. 2015, 386(9996):896–912.
3. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, et al. “Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology.” 2008, 71(7):474–80.
4. Tambasco N, Romoli M, Calabresi P. “Levodopa in Parkinson's Disease: Current Status and Future Developments.” Curr Neuropharmacol. 2018;16(8):1239-1252.
5. Romagnolo A, Merola A, Artusi CA, Rizzone MG, Zibetti M, Lopiano L. “Levodopa-Induced Neuropathy: A Systematic Review.” Mov Disord Clin Pract. 2019, 6(2):96-103.
6. Cotzias GC, van Woert MH, Schiffer LM: “Aromatic amino acids and modification of parkinsonism.” N Engl J Med. 1967;276(7):374–9.
7. Kalinderi K, Papaliagkas V, Fidani L. “Pharmacogenetics and levodopa induced motor complications.” Int J Neurosci. 2019, 129(4):384-392.
8. Connolly BS, Lang AE. “Pharmacological Treatment of Parkinson Disease: A Review.” JAMA. 2014;311(16):1670–1683.
9. Alborghetti M, Bianchini E, Carolis L, De Galli S, Pontieri FE, Rinaldi D. “Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings.” Neural Regen Res. 2024;19(1):16–21.
10. “Xadago (safinamide) prescribing information.” Louisville, Kentucky: U.S. WorldMeds, LLC; 2017.
11. https://go.drugbank.com/drugs/DB06654
12. Reich SG, Savitt JM. “Parkinson's Disease.” Med Clin North Am. 2019, 103(2):337-350.
13. https://go.drugbank.com/drugs/DB01235
14. Zhang K, Xue N, Shi X, Liu W, Meng J, Du Y. “A validated chiral liquid chromatographic method for the enantiomeric separation of safinamide mesilate, a new anti-Parkinson drug.” J Pharm Biomed Anal. 2011, 55(1):220-4.
15. WU Xue, BO Meng, SUN Xiaojing, FAN Yanlong, WANG Yajing, DONG Haifeng. “Determination of Genotoxic Impurities in Safinamide Mesylate by LC/MS[J].” Metrology Science and Technology, 2022, 66(11): 27-30.
16. J. Sharma M. Thakare, V. A. R. T. (2020). “Development and Validation of Stability Indicating RP-HPLC Method for Determination of Safinamide Mesylate.” Jordan Journal of Pharmaceutical Sciences, 13 no. 2.
17. Godasu SK, Rajashakar V, Jyothi GSVD, et al. “Determination of RP-HPLC Method for Safinamide: Its Bulk and Tablet Dosage Form.” Research & Reviews: A Journal of Drug Formulation, Development and Production. 2018; 5(3): 1–6p.
18. “Development And Validation Of RP-HPLC Method For Determination of Safinamide Mesylate And Nasal Spray Formulation.” (2024). African Journal of Biomedical Research, 27(4S), 13860-13871.
19. Srikanth, Gurram & Illendula, Santhosh. (2021). “RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF SAFINAMIDE IN API FORM AND MARKETED FORMULATION.” International Journal of Research - GRANTHAALAYAH. 10. 402-417.
20. Rushikesh Ugale, Sushil Patil, Vikas Shinde, Amol Gayke, Vaishnavi Ugale, “RP-HPLC Method Development and Validation for Determination of Safinamide in Bulk and Pharmaceutical Formulation,” Int. J. of Pharm. Sci., 2025, Vol 3, Issue 8, 1904-1917.
21. United States Pharmacopeia (2024). “USP Monographs, Levodopa. USP-NF. Rockville, MD: United States Pharmacopeia.”
22. United States Pharmacopeia (2023). “USP Monographs, Carbidopa and Levodopa Tablets. USP-NF. Rockville, MD: United States Pharmacopeia.”
23. United States Pharmacopeia (2022). “USP Monographs, Carbidopa and Levodopa Orally Disintegrating Tablets. USP-NF. Rockville, MD: United States Pharmacopeia.”
24. Indian Pharmacopoeia.Volume II "Government of India ministry of health and family 7 welfare, I published by Indian Pharmacopoeial commission”, Govemment of India Ghaziabad, 2018, 2420.
25. Elbarbry F, Nguyen V, Mirka A, Zwickey H, Rosenbaum R. “A new validated HPLC method for the determination of levodopa: Application to study the impact of ketogenic diet on the pharmacokinetics of levodopa in Parkinson's participants.” Biomed Chromatogr. 2019 Jan;33(1):e4382.
26. Nakmode, D.D., Youssef, S.H., Das, S. et al. “Analytical method for simultaneous quantification of levodopa and carbidopa in the injectable oleogel formulation by HPLC.” BMC Chemistry 19, 43 (2025).
27. Nutan Rao, B. M. (2020). “RP-HPLC Method development, Validation and Forced Degradation for Simultaneous estimation of Benserazide HCl and Levodopa in a Marketed Formulation.” International Journal of PharmTech Research, 13 no. 03, 206-216.
28. Ibrahim EA, Saad SS, Hegazy MA, Abdel Fattah LE, Marzouk HM. “A novel stability-indicating chromatographic quantification of the antiparkinsonian drug safinamide in its pharmaceutical formulation employing HPTLC densitometry and ion-pair HPLC-DAD.” BMC Chem. 2024 Nov 1;18(1):212.
29. Shrivastava A, Gupta VB. “Methods for the determination of limit of detection and limit of quantitation of the analytical methods.” Chron Young Sci. 2011;2(1):21–5.
30. Ali, E.A.; Ibrahim, M.A.; Iqbal, M.; Alsalahi, R.; Mostafa, G.A.; Al Jarboua, S. “Application of a Quality by Design Approach to Develop a Simple, Fast, and Sensitive UPLC-MS/MS Method for Quantification of Safinamide, an Antiparkinson’s Drug, in Plasma.” Separations 2023, 10, 474.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Isha S. Christian
Khyati College of Pharmacy, Gujarat Technological University, Ahmedabad, Gujarat, India.
Ms. Purvi Ramanuj
Department of Quality Assurance, Khyati College of Pharmacy, Gujarat Technological University, Ahmedabad, Gujarat, India.
Dr. Pragnesh Patani
Principal, Khyati College of Pharmacy, Gujarat Technological University, Ahmedabad, Gujarat, India.